Please assess the completion status of the following clinical trial:

Trial Title: Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of pPE in this pregnancy requiring delivery \< 37 weeks gestation: new or worsening hypertension \>20 weeks with proteinuria or other features suggestive of PE (abnormal haematological, biochemical parameters, fetal growth restriction (FGR) and/or abnormal sFlt:PlGF (\>85)).~* Biochemical / haematological cut-offs:~* Platelet count \<100 x109/L~* Alanine amino transferase \> 50units/L~* Creatinine \>90mmol/L~* FGR:~* Abdominal circumference (AC) / estimated fetal weight (EFW) \<3rd centile~* Or 2 of the following:~* AC/EFW \<10th centile~* AC/EFW crossing centiles by \>2 quartiles~* Cerebroplacental ratio \<5th centile~* Umbilical artery PI \>95th centile~* At time of randomisation:~* Postpartum, within 3 days of delivery~* Aged 18 years or over~* Able to provide informed consent~* Serum creatinine \<100 mmol/l~Exclusion Criteria:~* Inability to consent~* Known cardiac disease~* Contraindication to ACE inhibitors~* Renal artery stenosis

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational medicinal product (Type: EXPERIMENTAL): Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo once daily for 6 months postpartum
- Observational arm (Type: NO_INTERVENTION): For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).

Based on this trial design, predict the completion outcome and termination type (if applicable).